Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21761369 | 1.00 | CHRM2 (0.43) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL12614671 | 0.89 | HSD17B10 (0.51) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL16481774 | 0.89 | HSD17B10 (0.51) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL4474810 | 0.87 | HSD17B10 (0.47) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL3653276 | 0.84 | CHRM2 (0.49) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL3996176 | 0.82 | HSD17B10 (0.52) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL6418166 | 0.82 | NR1H2 (0.43) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL3639448 | 0.81 | CHRM2 (0.39) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL4702243 | 0.81 | NR1H2 (0.49) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL5182270 | 0.81 | HPGD (0.41) | CHRM2CHRM1CHRM3HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119677749-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-116438177-A | Targeted chimeric compounds, pharmaceutical compositions containing same, and preparation methods and uses thereof | 江苏亚虹医药科技股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022161166-A1 | TARGETING CHIMERIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2022-08-04 | — | — | WO | disclosed |
| CN-103270036-B | As antiparasitic isoxazoline derivative | ZOETIS LLC (US) | 2015-11-25 | — | — | CN | disclosed |
| CN-104583211-A | Compounds and methods for antiviral therapy | GILEAD SCIENCES INC | 2015-04-29 | — | — | CN | disclosed |
| US-20140213576-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-07-31 | — | — | US | disclosed |
| WO-2014111380-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-07-24 | — | — | WO | disclosed |
| CN-103270036-A | Isoxazoline derivatives as antiparasitic agents | PFIZER | 2013-08-28 | — | — | CN | disclosed |
| US-20130217664-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2013-08-22 | — | — | US | disclosed |
| WO-2013117645-A1 | IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2013-08-15 | — | — | WO | disclosed |
| US-6200978-B1 | FOR PREVENTING OR TREATING INFLAMMATORY DISEASES SUCH AS ARTHRITIS, PSORIASIS, ASTHMA, OR INFLAMMATORY BOWEL DISEASE, DISORDERS OF RESPIRATORY FUNCTION, GASTROINTESTINAL DISORDERS SUCH AS FUNCTIONAL BOWEL DISEASE, AS ANALGESICS | PFIZER INC. | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217664-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JAK1, IL6, JAK3 | CHRM2 361/4885CHRM1 559/4885CHRM3 1168/4885 |
| US-20140213576-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, IL6ST | CHRM2 3597/4885CHRM1 4237/4885CHRM3 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.